These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 9649353

  • 1. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ.
    J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353
    [Abstract] [Full Text] [Related]

  • 2. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.
    Arch Biochem Biophys; 1998 May 01; 353(1):16-28. PubMed ID: 9578596
    [Abstract] [Full Text] [Related]

  • 3. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y.
    Drug Metab Dispos; 1998 Mar 01; 26(3):261-6. PubMed ID: 9492390
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism.
    Venkatakrishnan K, Von Moltke LL, Greenblatt DJ.
    Biopharm Drug Dispos; 2002 Jul 01; 23(5):183-90. PubMed ID: 12116049
    [Abstract] [Full Text] [Related]

  • 5. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR, Lasker JM, Johnson EF, Raucy JL.
    Drug Metab Dispos; 2000 Mar 01; 28(3):354-9. PubMed ID: 10681382
    [Abstract] [Full Text] [Related]

  • 6. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.
    Pharmacogenetics; 1997 Apr 01; 7(2):103-13. PubMed ID: 9170147
    [Abstract] [Full Text] [Related]

  • 7. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
    Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ.
    Eur J Clin Pharmacol; 2001 Apr 01; 57(1):31-6. PubMed ID: 11372587
    [Abstract] [Full Text] [Related]

  • 8. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H, Shimada T.
    Arch Biochem Biophys; 1997 Oct 01; 346(1):161-9. PubMed ID: 9328296
    [Abstract] [Full Text] [Related]

  • 9. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
    Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ.
    J Pharmacol Exp Ther; 1995 Mar 01; 272(3):1076-81. PubMed ID: 7891318
    [Abstract] [Full Text] [Related]

  • 10. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.
    Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ.
    Drug Metab Dispos; 2000 Dec 01; 28(12):1493-504. PubMed ID: 11095589
    [Abstract] [Full Text] [Related]

  • 11. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD.
    J Pharmacol Exp Ther; 2000 May 01; 293(2):453-9. PubMed ID: 10773015
    [Abstract] [Full Text] [Related]

  • 12. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM, Verhoeven CH, Shimada T, Back DJ.
    J Pharmacol Exp Ther; 1998 Dec 01; 287(3):975-82. PubMed ID: 9864282
    [Abstract] [Full Text] [Related]

  • 13. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT.
    Br J Clin Pharmacol; 2001 Nov 01; 52(5):547-53. PubMed ID: 11736863
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes.
    Miyazawa M, Shindo M, Shimada T.
    Drug Metab Dispos; 2002 May 01; 30(5):602-7. PubMed ID: 11950794
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
    Baldwin SJ, Clarke SE, Chenery RJ.
    Br J Clin Pharmacol; 1999 Sep 01; 48(3):424-32. PubMed ID: 10510156
    [Abstract] [Full Text] [Related]

  • 19. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H, Inoue K, Shimada T.
    Xenobiotica; 1998 Feb 01; 28(2):103-15. PubMed ID: 9522436
    [Abstract] [Full Text] [Related]

  • 20. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways.
    Bort R, Macé K, Boobis A, Gómez-Lechón MJ, Pfeifer A, Castell J.
    Biochem Pharmacol; 1999 Sep 01; 58(5):787-96. PubMed ID: 10449188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.